To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Gilead's CAR T therapy

FDA approved Yescarta axicabtagene ciloleucel (KTE-C19) from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) to treat relapsed or refractory large B cell lymphoma after two or more lines of systemic

Read the full 332 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE